<生产厂家价格>

偏钒酸钠

偏钒酸钠用途

【用途一】
用作分析试剂和媒染剂
【用途二】
用于化肥、煤气脱硫、照相。也可用做媒染剂等。
【用途三】
过硼酸盐试剂，腐蚀抑制剂，植物接种，媒染剂，照相显影，制药。

偏钒酸钠名称

[ CAS 号 ]:
13718-26-8

[ 中文名 ]:
偏钒酸钠

[ 英文名 ]:
Sodium metavanadate

[中文别名 ]:

[英文别名 ]:

Vanadicacidsodiumsalt
Sodium metavanadate
Vanadate,sodium
Vanadium, olatodioxo-, sodium salt (1:1)
SODIUM MONOVANADATE
EINECS 237-272-7
Sodium (meta)vanadate
Sodium oxido(dioxo)vanadium
MFCD00011125
Natriummetavanadat

偏钒酸钠物理化学性质

[ 熔点 ]:
600 °C

[ 分子式 ]:
NaO₃V

[ 分子量 ]:
121.929

[ 精确质量 ]:
121.918480

[ PSA ]:
57.20000

[ 外观性状 ]:
白色粉末

[ 储存条件 ]:
室温

[ 稳定性 ]:
Stable.

偏钒酸钠MSDS

详细MSDS(安全技术说明书)

偏钒酸钠毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: YW1050000

CHEMICAL NAME :: Vanadic acid, monosodium salt

CAS REGISTRY NUMBER :: 13718-26-8

LAST UPDATED :: 199710

DATA ITEMS CITED :: 45

MOLECULAR FORMULA :: O3-V.Na

MOLECULAR WEIGHT :: 121.93

WISWESSER LINE NOTATION :: NA VA-O3

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 98 mg/kg

TOXIC EFFECTS :: Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 12 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 74600 ug/kg

TOXIC EFFECTS :: Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 36 mg/kg

TOXIC EFFECTS :: Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea Gastrointestinal - hypermotility, diarrhea

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 17 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 11 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - cat

DOSE/DURATION :: 7180 ug/kg

TOXIC EFFECTS :: Vascular - BP elevation not characterized in autonomic section Vascular - BP lowering not characterized in autonomic section

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 17 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 25851 ug/kg/6W-I

TOXIC EFFECTS :: Gastrointestinal - malabsorption Kidney, Ureter, Bladder - changes in bladder weight Nutritional and Gross Metabolic - changes in calcium

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 517 mg/kg/12W-I

TOXIC EFFECTS :: Gastrointestinal - other changes Liver - other changes Nutritional and Gross Metabolic - changes in metals, not otherwise specified

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3878 mg/kg/90D-I

TOXIC EFFECTS :: Cardiac - other changes Endocrine - other changes Biochemical - Neurotransmitters or modulators (putative) - catecholamine levels in CNS

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 718 mg/kg/30W-C

TOXIC EFFECTS :: Cardiac - pulse rate increase, without fall in BP Vascular - BP elevation not characterized in autonomic section Kidney, Ureter, Bladder - other changes in urine composition

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 25 mg/kg/5D-I

TOXIC EFFECTS :: Brain and Coverings - other degenerative changes

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 17500 ug/kg/10W-I

TOXIC EFFECTS :: Behavioral - changes in motor activity (specific assay) Gastrointestinal - decreased motility or constipation

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 1800 mg/kg

SEX/DURATION :: male 30 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 25 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 25 mg/kg

SEX/DURATION :: female 12 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 40 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 80 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

MUTATION DATA

TYPE OF TEST :: Sex chromosome loss and nondisjunction

TEST SYSTEM :: Human Lymphocyte

REFERENCE :: MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 319,205,1993 *** REVIEWS *** TOXICOLOGY REVIEW FRMBAZ Farmacia (Bucharest). (Rompresfilatelia, POB 12-201, Bucharest, Romania) V.1- 1953- Volume(issue)/page/year: 21,325,1973 TOXICOLOGY REVIEW 85DHAX "Medical and Biologic Effects of Environmental Pollutants Series," Washington, DC, National Academy of Sciences, 1972-77 Volume(issue)/page/year: V,46,1974 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-AUSTRALIA:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-BELGIUM:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-DENMARK:TWA 0.03 mg(V2O5)/m3 JAN 1993 OEL-FINLAND:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-FRANCE:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-GERMANY:TWA 0.05 mg(V2O5)/m3 JAN 1993 OEL-HUNGARY:TWA 0.05 mg(V2O5)/m3;STEL 0.1 mg(V205)/m3 JAN 1993 OEL-JAPAN:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-THE NETHERLANDS:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-THE PHILIPPINES:TWA 0.25 mg(V205)/m3 JAN 1993 OEL-POLAND:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-SWEDEN:STEL 0.05 mg(V2O5)/m3 JAN 1993 OEL-SWEDEN:TWA 0.2 mg(V2O5)/m3 (dust) JAN 1993 OEL-SWITZERLAND:TWA 0.05 mg(V2O5)/m3;STEL 0.25 mg(V2O5)/m3 JAN 1993 OEL-TURKEY:TWA 0.5 mg(V2O5)/m3 JAN 1993 OEL-UNITED KINGDOM:TWA 0.05 mg(V2O5)/m3 (dust) JAN 1993 OEL-UNITED KINGDOM:TWA 0.5 mg(V2O5)/m3 JAN 1993 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO VANADIUM (as V2O5), resp dust/fume-air:CL 0.05 mg/m3/15M REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992

偏钒酸钠安全信息

[ 符号 ]:

GHS06, GHS08, GHS09

[ 信号词 ]:
Danger

[ 危害声明 ]:
H301-H319-H332-H361fd-H372-H411

[ 警示性声明 ]:
P201-P261-P273-P280-P301 + P310 + P330-P304 + P340 + P312

[ 个人防护装备 ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges

[ 危害码 (欧洲) ]:
T: Toxic;

[ 风险声明 (欧洲) ]:
R25;R36/37/38

[ 安全声明 (欧洲) ]:
S26-S36/37/39-S45

[ 危险品运输编码 ]:
UN 3285 6.1/PG 3

[ WGK德国 ]:
3

[ RTECS号 ]:
YW1050000

[ 包装等级 ]:
II

[ 危险类别 ]:
6.1

偏钒酸钠制备

1.烧碱法将五氧化二钒溶解于氢氧化钠溶液中，经浓缩结晶，即得偏钒酸钠成品。

2.搅拌下，往10%的碳酸钠水溶液中慢慢加入理论量的钒酸铵，加热至沸：

当氨气不再生成并被赶尽时，添加蒸馏水，使溶液密度为1.25～1.28（ 50～60℃时），冷却至20～25℃结晶，结晶用冷水洗涤3～4次，并用无水乙醇洗涤2次，甩干，于40～50℃下干燥至乙醇气味完全消失为止。

偏钒酸钠文献

Alterations in brain neurotrophic and glial factors following early age chronic methylphenidate and cocaine administration.

Behav. Brain Res. 282 , 125-32, (2015)

Attention deficit hyperactivity disorder (ADHD) overdiagnosis and a pharmacological attempt to increase cognitive performance, are the major causes for the frequent (ab)use of psychostimulants in non-...

BDNF stimulation of protein synthesis in cortical neurons requires the MAP kinase-interacting kinase MNK1.

J. Neurosci. 35(3) , 972-84, (2015)

Although the MAP kinase-interacting kinases (MNKs) have been known for >15 years, their roles in the regulation of protein synthesis have remained obscure. Here, we explore the involvement of the MNKs...

Thymic Atrophy and Apoptosis of CD4+CD8+ Thymocytes in the Cuprizone Model of Multiple Sclerosis.

PLoS ONE 10 , e0129217, (2015)

Previous studies on the degenerative animal model of multiple sclerosis suggested that the copper-chelator cuprizone might directly suppress T-cell functions. Peripheral T-cell function in the cuprizo...

更多文献